Loading company…
Palobiofarma develops drugs that modulate adenosine receptors for various diseases.
Palobiofarma develops drugs that modulate adenosine receptors, with candidates for asthma, COPD, Prader-Willi Syndrome, and other conditions. Founded in 2006 and based in Barcelona, Spain, it raised EUR 7 million in February 2024, led by Inveready Asset Management with Sodena participating. Funding is intended to support three Phase II clinical trials.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in